Skip to main content
SpringerLink
Log in

Transferrin Level Before Treatment and Genetic Polymorphism in HFE Gene as Predictive Markers for Response to Adalimumab in Crohn’s Disease Patients

  • Original Article
  • Published:
Biochemical Genetics Aims and scope Submit manuscript

Abstract

Tumor necrosis factor α inhibitors (anti-TNF) have improved treatment of several complex diseases, including Crohn’s disease (CD). However, the effect varies and approximately one-third of the patients do not respond. Since blood parameters as well as genetic factors have shown a great potential to predict response during treatment, the aim of the study was to evaluate response to anti-TNF treatment with adalimumab (ADA) between genes HFE and TF and haematological parameters in Slovenian refractory CD patients. Single nucleotide polymorphisms (SNPs) rs1799852 in gene TF and rs2071303 in gene HFE were genotyped in 68 refractory CD patients for which response has been measured using inflammatory bowel disease questionnaire (IBDQ) index. Haematological parameters and IBDQ index were determined before therapy and after 4, 12, 20 and 30 weeks. We found novel strong association between SNP rs2071303 in gene HFE and response to ADA treatment, particularly patients with G allele comparing to A allele had better response after 20 weeks (p = 0.008). Further, we found strong association between transferrin level at baseline and treatment response after 12, 20 and 30 weeks, where average transferrin level before therapy was lower in responders (2.38 g/L) compared to non-responders (2.89 g/L, p = 0.005). Association was found between transferrin level in week 30 and SNP rs1799852 (p = 0.023), and between MCHC level before treatment and SNP rs2071303 (p = 0.007). Our results suggest that SNP in gene HFE as well as haematological markers serve as promising prognostic markers of response to anti-TNF treatment in CD patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  • Aalto K, Honkanen V, Lahdenne P (2011) Iron status during anti-TNF therapy in children with juvenile idiopathic arthritis. Clin Rheumatol 30:115–119. doi:10.1007/s10067-010-1571-7

    Article  PubMed  Google Scholar 

  • Benyamin B et al (2009) Variants in TF and HFE explain approximately 40% of genetic variation in serum-transferrin levels. Am J Hum Genet 84:60–65. doi:10.1016/j.ajhg.2008.11.011

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Feder JN et al (1998) The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc Natl Acad Sci USA 95:1472–1477

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gasche C, Lomer MC, Cavill I, Weiss G (2004) Iron, anaemia, and inflammatory bowel diseases. Gut 53:1190–1197. doi:10.1136/gut.2003.035758

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Guyatt G, Mitchell A, Irvine EJ, Singer J, Williams N, Goodacre R, Tompkins C (1989) A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 96:804–810

    Article  CAS  PubMed  Google Scholar 

  • Hetland ML et al (2010) Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO Registry. Arthritis Rheum 62:22–32. doi:10.1002/art.27227

    Article  CAS  PubMed  Google Scholar 

  • Hlavaty T, Persoons P, Vermeire S, Ferrante M, Pierik M, van Assche G, Rutgeerts P (2006) Evaluation of short-term responsiveness and cutoff values of inflammatory bowel disease questionnaire in Crohn’s disease. Inflamm Bowel Dis 12:199–204

    Article  PubMed  Google Scholar 

  • Khusainova RI, Khusnutdinova NN, Litvinov SS, Khusnutdinova EK (2013) Analysis of H63D mutation in hemochromatosis (HFE) gene in populations of central Eurasia. Genetika 49:269–278

    CAS  PubMed  Google Scholar 

  • Koder S, Repnik K, Ferkolj I, Pernat C, Skok P, Weersma RK, Potočnik U (2015) Genetic polymorphism in ATG16L1 gene influences the response to adalimumab in Crohn’s disease patients. Pharmacogenomics 16:191–204. doi:10.2217/pgs.14.172

    Article  CAS  PubMed  Google Scholar 

  • Määttä KM, Nikkari ST, Kunnas TA (2015) Genetic variant coding for iron regulatory protein HFE contributes to hypertension, the TAMRISK study. Medicine (Baltim) 94:e464. doi:10.1097/MD.0000000000000464

    Article  Google Scholar 

  • Mack DR et al (2007) Laboratory values for children with newly diagnosed inflammatory bowel disease. Pediatrics 119:1113–1119. doi:10.1542/peds.2006-1865

    Article  PubMed  Google Scholar 

  • McLaren CE et al (2011) Genome-wide association study identifies genetic loci associated with iron deficiency. PLoS One 6:e17390. doi:10.1371/journal.pone.0017390

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Minaur NJ, Jacoby RK, Cosh JA, Taylor G, Rasker JJ (2004) Outcome after 40 years with rheumatoid arthritis: a prospective study of function, disease activity, and mortality. J Rheumatol Suppl 69:3–8

    PubMed  Google Scholar 

  • Moczulski DK, Grzeszczak W, Gawlik B (2001) Role of hemochromatosis C282Y and H63D mutations in HFE gene in development of type 2 diabetes and diabetic nephropathy. Diabetes Care 24:1187–1191

    Article  CAS  PubMed  Google Scholar 

  • Papadaki HA, Kritikos HD, Valatas V, Boumpas DT, Eliopoulos GD (2002) Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improvement following anti-tumor necrosis factor-alpha antibody therapy. Blood 100:474–482. doi:10.1182/blood-2002-01-0136

    Article  CAS  PubMed  Google Scholar 

  • Parkkila S et al (1997) Immunohistochemistry of HLA-H, the protein defective in patients with hereditary hemochromatosis, reveals unique pattern of expression in gastrointestinal tract. Proc Natl Acad Sci USA 94:2534–2539

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Rong Y et al (2012) Hemochromatosis gene (HFE) polymorphisms and risk of type 2 diabetes mellitus: a meta-analysis. Am J Epidemiol 176:461–472. doi:10.1093/aje/kws126

    Article  PubMed  Google Scholar 

  • Rosenblum H, Amital H (2011) Anti-TNF therapy: safety aspects of taking the risk. Autoimmun Rev 10:563–568. doi:10.1016/j.autrev.2011.04.010

    Article  PubMed  Google Scholar 

  • Rubin DT, Mulani P, Chao J, Pollack PF, Bensimon AG, Yu AP, Ghosh S (2012) Effect of adalimumab on clinical laboratory parameters in patients with Crohn’s disease: results from the CHARM trial. Inflamm Bowel Dis 18:818–825. doi:10.1002/ibd.21836

    Article  PubMed  Google Scholar 

  • Rusten LS, Jacobsen SE (1995) Tumor necrosis factor (TNF)-alpha directly inhibits human erythropoiesis in vitro: role of p55 and p75 TNF receptors. Blood 85:989–996

    CAS  PubMed  Google Scholar 

  • Sobolewska A, Włodarczyk M, Stec-Michalska K, Fichna J, Wiśniewska-Jarosińska M (2015) Mean platelet volume in Crohn’s disease patients predicts sustained response to a 52-week infliximab therapy: a pilot study. Dig Dis Sci. doi:10.1007/s10620-015-3894-3

    PubMed  PubMed Central  Google Scholar 

  • Trinder MW, Lawrance IC (2009) Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting. J Gastroenterol Hepatol 24:1252–1257

    Article  CAS  PubMed  Google Scholar 

  • Waheed A et al (1997) Hereditary hemochromatosis: effects of C282Y and H63D mutations on association with beta2-microglobulin, intracellular processing, and cell surface expression of the HFE protein in COS-7 cells. Proc Natl Acad Sci USA 94:12384–12389

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zorzi F et al (2012) Efficacy and safety of infliximab and adalimumab in Crohn’s disease: a single centre study. Aliment Pharmacol Ther 35:1397–1407

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Human Molecular Genetics and Pharmacogenomics, Faculty of Medicine, University of Maribor, Taborska ulica 8, 2000, Maribor, Slovenia

    Katja Repnik & Uroš Potočnik

  2. Laboratory for Biochemistry, Molecular Biology and Genomics, Faculty for Chemistry and Chemical Engineering, University of Maribor, Smetanova ulica 17, 2000, Maribor, Slovenia

    Katja Repnik & Uroš Potočnik

  3. University Medical Centre Maribor, Ljubljanska ulica 5, 2000, Maribor, Slovenia

    Silvo Koder & Pavel Skok

  4. University Medical Centre Ljubljana, Zaloška cesta 2, 1000, Ljubljana, Slovenia

    Ivan Ferkolj

Authors
  1. Katja Repnik
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Silvo Koder
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pavel Skok
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ivan Ferkolj
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Uroš Potočnik
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Uroš Potočnik.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Repnik, K., Koder, S., Skok, P. et al. Transferrin Level Before Treatment and Genetic Polymorphism in HFE Gene as Predictive Markers for Response to Adalimumab in Crohn’s Disease Patients. Biochem Genet 54, 476–486 (2016). https://doi.org/10.1007/s10528-016-9734-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10528-016-9734-0

Keywords

Search

Navigation